JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. TNGX | 0.00 |
JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:
TNGX) with a Overweight rating and announces Price Target of $46.
